The incidence of cancer is relatively low (2.6%) in individuals over 60 with no anti-TIF-1 or anti-NXP-2 autoantibodies, but it is greater (11%) in patients under 60 with anti-TIF-1 or anti-NXP-2 autoantibodies [34]. This evidence concerns the gene TRIM24 and cancer.